Momentary Associations Across Specific Affective States and Dysregulated Eating Experiences Among Children and Adolescents With Loss of Control Eating Symptoms.

Objective: Dysregulated eating is common among youth and is associated with trait-level negative affect and emotion regulation difficulties. Despite the transient nature of affect, momentary associations among affect and eating behavior are unclear, which limits development of more impactful treatment tools, such as "just-in-time" intervention approaches (JITAI). The current study (N = 62) drew from two ecological momentary assessment (EMA) studies involving children and adolescents who endorsed loss of control (LOC) eating symptoms during a two-week assessment period.

Efficacy of emicizumab in patients with severe haemophilia A without factor VIII inhibitors in Germany: evaluation of real-life data documented by the smart medication eDiary.

Background: Systematically documented data on real-world use of emicizumab, a bispecific antibody factor (F)VIII mimetic, are still lacking in people with severe haemophilia A (PwSHA). Smart medication, a real-time, online platform, monitors treatment administration and outcomes for people with haemophilia A in Germany.

Objective: To evaluate annualised bleeding rates (ABRs) and annualised joint bleeding rates (AJBRs), using data documented in the smart medication eDiary, for PwSHA receiving emicizumab.

Multi-institutional Validation of the Interarytenoid Assessment Protocol for Pediatric Laryngeal Cleft.

Background: Current assessment techniques for determining whether a patient has normal interarytenoid anatomy, a deep interarytenoid notch, or a minor laryngeal cleft are highly variable. However, differentiating between these three entities is important, given it may distinguish whether a patient should be considered for surgical intervention. The Interarytenoid Assessment Protocol (IAAP) was developed to provide standardization of interarytenoid anatomy evaluations.

Treatment of Cancer-Associated Thrombosis: An Update.

Patients with cancer are at increased risk of venous thromboembolism (VTE). Treatment of VTE remains challenging due to a significant risk of both VTE recurrence and bleeding compared with patients without underlying malignancy. Moreover, patients with cancer often present with several comorbidities such as tumor- or treatment-induced bone marrow failure, renal impairment, and extensive concomitant anticancer or supportive medication, resulting in potential drug-drug interactions.